<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01866644</url>
  </required_header>
  <id_info>
    <org_study_id>NAC400</org_study_id>
    <nct_id>NCT01866644</nct_id>
  </id_info>
  <brief_title>Effectiveness of N-acetylcysteine on Preservation Solution During Liver Transplantation</brief_title>
  <official_title>Effectiveness of N-acetylcysteine on Preservation Solution During Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigacion Sanitaria La Fe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigacion Sanitaria La Fe</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effectiveness of the administration produced antioxidant N-acetylcysteine (NAC),
      decreasing the incidence of primary graft dysfunction and primary failure. The degree of
      dysfunction will be monitored by the method of LIMON, metabonomics techniques and according
      to the latest published validation Liver Transplantation (16 943-949 2010), total
      billirrubina greater than 10 mg / dl, INR greater than 1.6 in the seventh postoperative day
      and alanine or aspartate aminotransferase greater than 2000 IU / L in the first seven days.
      Liver dysfunction is considered, the presence of a transaminase value&gt; 2000 IU / L 1-7
      postoperative day or BT&gt; 10 mg / dl or INR&gt; 1.6, both only in the 7th postoperative day
      (Olthoff et al Liver Transplantation 16,943 -949 2010).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The reason of this study is to evaluate the efficacy of the use of n-acetylcysteine in liver
      transplant, by administering it in the perfusion liquid, at the time of extraction of the
      liver of the donor to improve the damage caused by ischemia / reperfusion. The dose is 400 mg
      in the portal perfusion liquid.

      The study included all considered valid and perfused livers. Patients are randomized to
      contain no drug or n-acetylcysteine by randomization. Then analyzed using blood tests and in
      the receiver and daily during the first seven days post-transplant hepatic dysfunction
      parameters, in order to objectify if liver function improves after administration of the
      antioxidant (n-acetylcysteine ). Safety assessments were performed with intraoperative
      monitoring anesthetic depth, postoperative parameters of liver and kidney function and graft
      pathologic examination after perfusion.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of primary graft dysfunction and primary failure</measure>
    <time_frame>One week after treatment</time_frame>
    <description>Evaluate the incidence of primary graft dysfunction and primary failure in each group of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the existence of side effects from the use of n-acetylcysteine on liver preservation solution usual.</measure>
    <time_frame>One week after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of postoperative renal disfunction</measure>
    <time_frame>One week after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess levels of glutathione stores achieved following administration of NAC</measure>
    <time_frame>During harvesting</time_frame>
    <description>During the harvesting and implantation in the recipient liver three liver biopsies will be performed which will be assessed by determining metabonomics metabolites of the transsulfuration pathway and GSH levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological changes</measure>
    <time_frame>During harvesting</time_frame>
    <description>Two biopsies which are going to be done in donor graft before and after reperfusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Unspecified Complication of Liver Transplant</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At portal level, a cannula is inserted with the usual technique of infusion of 3000 ml of preservation fluid to free fall as containing or not scrambling inserted by the NAC scrub nurse then (400 mg of N-acetylcysteine at 10%, 4 ml ).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>With usual technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>Bath transplanted liver with N-acetylcysteine</description>
    <arm_group_label>N-acetylcysteine</arm_group_label>
    <other_name>Flumil Solution injectable 300 Mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Bath saline transplanted liver</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>It's not describe in a protocol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All grafts perfused by extraction for liver transplantation.

        Exclusion Criteria:

          -  &lt; 18 years

          -  Allergy to NAC

          -  Grafts considered invalid for liver transplantation after perfusion

          -  Hepatitis fulminant

          -  Retransplantation

          -  Split

          -  &gt; 10 hours of cold ischemia

          -  Patients with asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Lopez Andujar, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Concepcion Gómez i Gavara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci. 2003 Jan;60(1):6-20. Review.</citation>
    <PMID>12613655</PMID>
  </reference>
  <reference>
    <citation>De Rosa SC, Zaretsky MD, Dubs JG, Roederer M, Anderson M, Green A, Mitra D, Watanabe N, Nakamura H, Tjioe I, Deresinski SC, Moore WA, Ela SW, Parks D, Herzenberg LA, Herzenberg LA. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest. 2000 Oct;30(10):915-29.</citation>
    <PMID>11029607</PMID>
  </reference>
  <reference>
    <citation>Abstracts of the Brain Research Association meeting, Mechanisms of Recovery of Function after Brain Damage. Oxford, U.K., 11 January 1988. Neurosci Lett Suppl. 1988;32:S107-17.</citation>
    <PMID>2897100</PMID>
  </reference>
  <reference>
    <citation>Himmelfarb J, Hakim RM. Oxidative stress in uremia. Curr Opin Nephrol Hypertens. 2003 Nov;12(6):593-8. Review.</citation>
    <PMID>14564195</PMID>
  </reference>
  <reference>
    <citation>Molnar Z, Szakmany T, Koszegi T. Prophylactic N-acetylcysteine decreases serum CRP but not PCT levels and microalbuminuria following major abdominal surgery. A prospective, randomised, double-blinded, placebo-controlled clinical trial. Intensive Care Med. 2003 May;29(5):749-55. Epub 2003 Apr 8.</citation>
    <PMID>12682719</PMID>
  </reference>
  <reference>
    <citation>Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003 Dec;42(6):1075-81. Epub 2003 Oct 27. Review.</citation>
    <PMID>14581295</PMID>
  </reference>
  <reference>
    <citation>Raj DS, Lim G, Levi M, Qualls C, Jain SK. Advanced glycation end products and oxidative stress are increased in chronic allograft nephropathy. Am J Kidney Dis. 2004 Jan;43(1):154-60.</citation>
    <PMID>14712439</PMID>
  </reference>
  <reference>
    <citation>Rank N, Michel C, Haertel C, Lenhart A, Welte M, Meier-Hellmann A, Spies C. N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study. Crit Care Med. 2000 Dec;28(12):3799-807.</citation>
    <PMID>11153617</PMID>
  </reference>
  <reference>
    <citation>Taut FJ, Schmidt H, Zapletal CM, Thies JC, Grube C, Motsch J, Klar E, Martin E. N-acetylcysteine induces shedding of selectins from liver and intestine during orthotopic liver transplantation. Clin Exp Immunol. 2001 May;124(2):337-41.</citation>
    <PMID>11422213</PMID>
  </reference>
  <reference>
    <citation>Thies JC, Teklote J, Clauer U, Töx U, Klar E, Hofmann WJ, Herfarth C, Otto G. The efficacy of N-acetylcysteine as a hepatoprotective agent in liver transplantation. Transpl Int. 1998;11 Suppl 1:S390-2.</citation>
    <PMID>9665023</PMID>
  </reference>
  <reference>
    <citation>Marczin N, Bundy RE, Hoare GS, Yacoub M. Redox regulation following cardiac ischemia and reperfusion. Coron Artery Dis. 2003 Apr;14(2):123-33. Review.</citation>
    <PMID>12655276</PMID>
  </reference>
  <reference>
    <citation>Selzner N, Rudiger H, Graf R, Clavien PA. Protective strategies against ischemic injury of the liver. Gastroenterology. 2003 Sep;125(3):917-36. Review.</citation>
    <PMID>12949736</PMID>
  </reference>
  <reference>
    <citation>D'Amico F, Vitale A, Gringeri E, Valmasoni M, Carraro A, Brolese A, Zanus G, Boccagni P, D'Amico DF, Cillo U. Liver transplantation using suboptimal grafts: impact of donor harvesting technique. Liver Transpl. 2007 Oct;13(10):1444-50.</citation>
    <PMID>17902131</PMID>
  </reference>
  <reference>
    <citation>Lopez-Andujar R, Deusa S, Montalvá E, San Juan F, Moya A, Pareja E, DeJuan M, Berenguer M, Prieto M, Mir J. Comparative prospective study of two liver graft preservation solutions: University of Wisconsin and Celsior. Liver Transpl. 2009 Dec;15(12):1709-17. doi: 10.1002/lt.21945.</citation>
    <PMID>19938119</PMID>
  </reference>
  <reference>
    <citation>Pedotti P, Cardillo M, Rigotti P, Gerunda G, Merenda R, Cillo U, Zanus G, Baccarani U, Berardinelli ML, Boschiero L, Caccamo L, Calconi G, Chiaramonte S, Dal Canton A, De Carlis L, Di Carlo V, Donati D, Montanaro D, Pulvirenti A, Remuzzi G, Sandrini S, Valente U, Scalamogna M. A comparative prospective study of two available solutions for kidney and liver preservation. Transplantation. 2004 May 27;77(10):1540-5. Erratum in: Transplantation. 2004 Aug 15;78(3):489.</citation>
    <PMID>15239618</PMID>
  </reference>
  <reference>
    <citation>Varadarajan R, Golden-Mason L, Young L, McLoughlin P, Nolan N, McEntee G, Traynor O, Geoghegan J, Hegarty JE, O'Farrelly C. Nitric oxide in early ischaemia reperfusion injury during human orthotopic liver transplantation. Transplantation. 2004 Jul 27;78(2):250-6.</citation>
    <PMID>15280686</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2012</study_first_submitted>
  <study_first_submitted_qc>May 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2013</study_first_posted>
  <last_update_submitted>July 21, 2015</last_update_submitted>
  <last_update_submitted_qc>July 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver transplantation, n-acetylcysteine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

